Abstract
Dendritic cells(DCs) are recognized as the most potent antigen-presenting cells and methods for delivering tumor antigens into DCs are one of the major concerns of intensive investigation in DC-based tumor vaccines. Fusion of DCs with tumor cells is an effective approach for delivering tumor antigens to DCs, and DC-tumor fusion cells are potent stimulators of immune response against tumor cells. We compared anti-tumor immune response of the DC-tumor fusion cells versus the tumor lysate-pulsed DCs in hormone refractory prostate cancer cell lines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
